Patient recruitment: Accelarating pharmaceutical's drive to market

Abstract

With increasing industry pressure to develop, test and market greater numbers of new drugs faster, pharmaceutical companies need to perform clinical trials as quickly as possible. However, inefficient patient recruitment processes are already formidable barriers to successful product launches - and may become even more detrimental as trial complexity grows. Based on a recent international study researchers suggest that pharmaceutical companies rethink patient recruitment, focusing on five imperatives that can help them avoid wasted investments and eliminate costly delays in bringing new drugs to market.